Therapy News and Research

RSS

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Cardiac resynchronization therapy improves sexual health in men with chronic heart failure

A new study published in the journal Clinical Cardiology reveals that in men with chronic heart failure, cardiac resynchronization therapy improves patients' libido, erectile dysfunction, and sexual performance.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

PCR-based saliva test can accurately identify cytomegalovirus infection in newborns

Although cytomegalovirus infection is a known cause of birth defects, including permanent hearing loss, most CMV infections in infants are not identified early, when interventions can lessen the effects of hearing loss.

2 Jun 2011

Kindred acquires RehabCare

Kindred Healthcare, Inc. announced that it has completed the previously announced acquisition of RehabCare Group, Inc.

2 Jun 2011

IMRT cuts GI side effects from prostate cancer in half vs. 3D-CRT

Intensity modulated radiation therapy, a newer, more precise form of radiation therapy, causes fewer gastrointestinal side effects when combined with hormone therapy than using three-dimensional radiation therapy, according to a study published in the June issue of the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

1 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Men with migraine suffer from PTSD than women

A recently published paper highlights that while the risk of post-traumatic stress disorder (PTSD) is more common in those with migraine than those without migraine irrespective of sex, the risk is greater in male migraineurs than female migraineurs. Study details are now available in Headache: The Journal of Head and Face Pain, published by Wiley-Blackwell on behalf of the American Headache Society.

1 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration.

1 Jun 2011

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Pfizer Inc. announced today that the European Medicines Agency has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma after failure of prior systemic treatment.

1 Jun 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

1 Jun 2011

Shield raises EUR8.2M through Series A financing

Shield Therapeutics, the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised EUR8.2m from Inventages Venture Capital (Inventages) in its first institutional financing round.

1 Jun 2011

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

Although gynecologic cancers account for only 10 percent of all new cancer cases in women, these cancers account for 20 percent of all female cancer survivors. Because long-term survival is now more common, it is increasingly important to detect recurrence.

1 Jun 2011

New genetic test can predict clinical outcomes in glioblastoma patients

New research proves that a change in a particular gene can identify which patients with a specific kind of brain cancer will respond better to treatment. Testing for the gene can distinguish patients with a more- or less-aggressive form of glioblastoma, the most common and an often-fatal type of primary brain cancer, and help guide therapy, the researchers say.

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

NIH scientists discuss expanded HIV testing and new prevention tools

In the 30 years since the first reported cases of a mysterious illness now known as AIDS, researchers have made extraordinary advances in understanding, treating and preventing the disease.

1 Jun 2011

Diamyd European Phase III study in diabetes does not meet primary endpoint

Diamyd Medical AB reports that the Company has decided not to complete the follow-up period of a European Phase III study with the antigen-based therapy Diamyd.

1 Jun 2011

Therapy News and Research

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Cardiac resynchronization therapy improves sexual health in men with chronic heart failure

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

PCR-based saliva test can accurately identify cytomegalovirus infection in newborns

Kindred acquires RehabCare

IMRT cuts GI side effects from prostate cancer in half vs. 3D-CRT

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Men with migraine suffer from PTSD than women

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Shield raises EUR8.2M through Series A financing

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

New genetic test can predict clinical outcomes in glioblastoma patients

Lymphoma vaccine extends disease-free survival by 14 months

NIH scientists discuss expanded HIV testing and new prevention tools

Diamyd European Phase III study in diabetes does not meet primary endpoint

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News